Severe case and literature review of primary erythromelalgia: Novel SCN9A gene mutation

Vascular Medicine

Volumn 17, Issue 1, 2012, Pages 44-49

  Skeik, Nedaa ^a   Rooke, Thom W ^a   Davis, Mark Denis P ^a   Davis, Dawn Marie R ^a   Kalsi, Henna ^a   Kurth, Ingo ^b   Richardson, Randal C ^c  

^a MAYO CLINIC   (United States)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Seattle Children's B 5552 Neurology   (United States)

Author keywords

erythromelalgia; genetic mutations; sodium channelopathy

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; ERGOT ALKALOID; GABAPENTIN; GLUTAMIC ACID; GLUTAMINE; ILOPROST; MAGNESIUM; MERCURY; NARCOTIC AGENT; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; NOREPHEDRINE; PERGOLIDE; PREGABALIN; PROSTAGLANDIN E1; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL NAV1.7; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ADOLESCENT; AMINO ACID SUBSTITUTION; ASTROCYTOMA; AUTOSOMAL DOMINANT INHERITANCE; BLOOD DISEASE; CASE REPORT; CHANNELOPATHY; CONNECTIVE TISSUE DISEASE; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; ERYTHROMELALGIA; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HUMAN; INGESTION; MERCURIALISM; MISSENSE MUTATION; MULTIPLE SCLEROSIS; MUSHROOM; MYELOPROLIFERATIVE DISORDER; NEUROFIBROMATOSIS; NUCLEOTIDE SEQUENCE; PAIN; PARANEOPLASTIC SYNDROME; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMOMA; VASCULITIS;

ADOLESCENT; AMINO ACID SEQUENCE; ERYTHROMELALGIA; FEMALE; HUMANS; MUTATION, MISSENSE; PAIN; SODIUM CHANNELS;

EID: 84857613952     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X11422584     Document Type: Review

References (35)

1. Mitchell SW. On a rare vaso-motor neurosis of the extremities and on the maladies with which it may be confounded. Am J Med Sci. 1878 ; 76: 17
2. Graves RJ Dublin: Fannin ; 1834 :
3. Smith LA, Allen EV. Erythermalgia (erythromelalgia), of the extremities: a syndrome characterized by redness, heat and pain. Am Heart J. 1938 ; 16: 175-188
4. Lewis T. Clinical observation and experiments relating to burning pain in extremities and to so-called 'erythromelalgia' in particular. Clin Sci. 1933 ; 1: 175-211
5. Albuquerque LG, França ER, Kozmhinsky V, Querino MC, Morais AG. Primary erythromelalgia: case report. An Bras Dermatol. 2011 ; 86: 131-134
6. Davis MD, O'Fallon WM, Rogers RS, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000 ; 136: 330-336 (Pubitemid 30149105)
7. Mørk C, Kalgaard OM, Kvernebo K. Erythromelalgia: a clinical study of 102 cases (abstract). Australas J Dermatol. 1997 ; 38 (suppl 2). 50
8. Kvernebo K. Erythromelalgia: a condition caused by microvascular arteriovenous shunting. VASA-J Vasc Dis Suppl. 1998 ; 51: 1-39
9. Reed KB, Davis MD. Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2009 ; 23: 13-15
10. Novella SP, Hisama FM, Dib-Hajj SD, Waxman SG. A case of inherited erythromelalgia. Nat Clin Pract Neurol. 2007 ; 3: 229-234 (Pubitemid 46605273)
11. Dib-Hajj SD, Rush AM, Cummins TR, et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005 ; 128 (Pt 8). 1847-1854 (Pubitemid 41373656)
12. Davis MP, Rooke TW Vascular medicine: a companion to Braunwald's heart disease. Creager MA Dzau VJ Loscalzo J, ed. Philadelphia, PA: Elsevier, Inc. ; 2006: 711-721.
13. Latessa V. Erythromelalgia: a rare microvascular disease. J Vasc Nurs. 2010 ; 28: 67-71
14. Sangameswaran LM, Fish BD, Koch DK, et al. A novel tetrodotoxin- sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J Biol Chem. 1997 ; 272: 14,805-14,809
15. Dabby R, Sadeh M, Gilad R, et al. Chronic non-paroxysmal neuropathic pain-novel phenotype of mutation in the sodium channel. J Neurol Sci. 2011 ; 301: 90-92
16. Han C, Dib-Hajj SD, Lin Z, et al. Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation. Brain. 2009 ; 132 (Pt 7). 1711-1722
17. Lee MJ, Yu HS, Hsieh ST, Stephenson DA, Lu CJ, Yang CC. Characterization of a familial case with primary erythromelalgia from Taiwan. J Neurol. 2007 ; 254: 210-214 (Pubitemid 46356054)
18. Estacion M, Choi JS, Eastman EM, et al. Can robots patch-clamp as well as humans? Characterization of a novel sodium channel mutation. J Physiol. 2010 ; 588: 1915-1927
19. Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007 ; 117: 3603-3609 (Pubitemid 350224065)
20. Ahn HS, Dib-Hajj SD, Cox JJ, et al. A new Nav1.7 sodium channel mutation I234T in a child with severe pain. Eur J Pain. 2010 ; 14: 944-950
21. Lampert A, Dib-Hajj SD, Tyrrell L, Waxman SG. Size matters: erythromelalgia mutation S241T in Nav1.7 alters channel gating. J Biol Chem. 2006 ; 281: 36,029-36,035
22. Fischer TZ, Gilmore ES, Estacion M, Eastman E. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol. 2009 ; 65: 733-741
23. Lampert A, Dib-Hajj SD, Eastman EM, et al. Erythromelalgia mutation L823R shifts activation and inactivation of threshold sodium channel Nav1.7 to hyperpolarized potentials. Biochem Biophys Res Commun. 2009 ; 390: 319-324
24. Harty TP, Dib-Hajj SD, Tyrrell L, et al. Na(V)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J Neurosci. 2006 ; 26: 12,566-12,575
25. Choi JS, Zhang L, Dib-Hajj SD, et al. Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off. Exp Neurol. 2009 ; 216: 383-389
26. Cheng X, Dib-Hajj SD, Tyrrell L, Wright DA, Fischer TZ, Waxman SG. Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na V 1.7 produce distinct pain disorders. Mol Pain. 2010 ; 6: 24
27. Estacion M, Dib-Hajj SD, Benke PJ, et al. NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci. 2008 ; 28: 11,079-11,088
28. Klugbauer N, Lacinova L, Flockerzi V, Hofmann F. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J. 1995 ; 14: 1084-1090
29. Mørk C, Kvernebo K, Asker CL, Salerud EG. Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism. J Invest Dermatol. 2002 ; 119: 949-953 (Pubitemid 35340923)
30. Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol. 2000 ; 43 (5 Pt 1). 841-847
31. Davis MD, Rooke T. Erythromelalgia. Curr Treat Options Cardiovasc Med. 2006 ; 8: 153-165
32. Stone JD, Rivey MP, Allington DR. Nitroprusside treatment of erythromelalgia in an adolescent female. Ann Pharmacother. 1997 ; 31: 590-592 (Pubitemid 27203959)
33. Zhang L, Wang WH, Li LF, et al. Long-term remission of primary erythermalgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy. Eur J Dermatol. 2010 ; 20: 763-767
34. Chakravarty K, Pharoah PD, Scott DG, Barker S. Erythromelalgia-the role of hypnotherapy. Postgrad Med J. 1992 ; 68: 44-46
35. Cimaz R, Rusconi R, Fossali E, Careddu P. Unexpected healing of cutaneous ulcers in a short child. Lancet. 2001 ; 358: 211-212 (Pubitemid 32718549)